Climb Bio, Inc.
CLYMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeClimb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. Valued at $913.2M, CLYM is a small-cap name in its sector. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Market Cap
$913.2M
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
-15.85
EPS (TTM)
$-0.82
EPS (Fwd)
$-1.00
ROE
-27.1%
ROA
-18.4%
Cash
$183.1M
Total Debt
$1.3M
Free CF
-$34.0M
52W Change
552.1%
Annual Financials
Cash vs Debt
Where CLYM stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, CLYM finished 35.00% above its 150-day moving average ($10.17) and 62.49% above its 200-day moving average ($8.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLYM overbought or oversold?
At the September 1, 2026 close, CLYM's RSI(14) was 49.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $183.1M in cash and $1.3M in debt, CLYM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$34.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -27.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
CLYM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CLYM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CLYM.